As the United Nations gears up for a high-level meeting on combating a global tuberculosis epidemic, Doctors Without Borders is urging Johnson & Johnson (JNJ) to widen access for a medicine that the advocacy group maintained is too costly for many countries.

In a Sept. 17 letter to the company, Doctors Without Borders argued that an “affordable and sustainable” supply of Sirturo is increasingly needed, especially after the World Health Organization recently recommended the drug as the backbone for treating multi-drug resistant tuberculosis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Every entrance to a J&J building has a big copy of their vaunted Credo hanging on the wall, and their CEO’s rarely miss an opportunity to humblebrag about it. But when it comes down to it…

    • Hi Bruce,
      Yes, the credo plaque in New Brunswick is a good reference point for many discussion.
      Cheers
      ed at pharmalot

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy